iCRT 14

• CAT Number: I004548
• CAS Number: 677331-12-3
• Molecular Formula: C21H17N3O2S
• Molecular Weight: 375.40
• Purity: ≥95%
• Synonyms: iCRT 14; iCRT-14
• Target: Wnt
• Solubility: DMSO: ≥ 50 mg/mL
• Storage: Store at -20°C
• IC50: 40.3 nM
• IUPAC Name: (5Z)-5-[(2,5-dimethyl-1-pyridin-3-ylpyrrol-3-yl)methylidene]-3-phenyl-1,3-thiazolidine-2,4-dione
• InChI: InChI=1S/C21H17N3O2S/c1-14-11-16(15(2)23(14)18-9-6-10-22-13-18)12-19-20(25)24(21(26)27-19)17-7-4-3-5-8-17/h3-13H,1-2H3/b19-12-
• InChIKey: NCSHZXNGQYSKLR-UNOMPAQXSA-N
• SMILES: CC1=CC(=C(N1C2=CN=CC=C2)C)/C=C\3/C(=O)N(C(=O)S3)C4=CC=CC=C4

iCRT 14（Cat No.:I004548）is a small molecule inhibitor that targets the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. It specifically inhibits the activity of the IκB kinase (IKK) complex, which plays a key role in NF-κB activation. NF-κB is involved in inflammation, immune response, and cancer progression. By blocking IKK, iCRT 14 suppresses NF-κB signaling, which may reduce inflammation and hinder tumor growth. iCRT 14 is studied in cancer and inflammatory disease research for its potential therapeutic applications in modulating NF-κB-driven pathways.